
https://www.science.org/content/blog-post/new-improved-now-stickier-lumps
# "New! Improved! Now With Stickier Lumps!" (November 2002)

## 1. SUMMARY

This article describes the perennial tension in pharmaceutical research between medicinal chemists who synthesize new drug compounds and the formulation scientists who must prepare these compounds for dosing in animals. The author explains the formulation hierarchy: ideal compounds dissolve in aqueous solutions (possibly with co-solvents like PEG), while problematic "insoluble gumballs" require increasingly desperate measures including detergents, polysaccharides, and suspensions. The piece highlights that suspensions are tricky—prone to batch variability, particle size issues, polymorphism, and sedimentation—but compounds that work as suspensions predict better tablet performance than solution-only formulations, pointing to serious bioavailability problems ahead.

## 2. HISTORY

The core formulation challenges described in 2002 remain central to drug development today, though the arsenal of solutions has evolved significantly:

**Continued Industry Struggle**: Poor aqueous solubility remains a major cause of drug development failure. Industry surveys consistently show that 40-70% of new chemical entities face significant bioavailability challenges due to inadequate solubility, making this one of the most persistent problems in pharmaceutical development.

**Technology Evolution**: Several strategies have become standard since 2002. **Amorphous solid dispersions** (ASDs) emerged as a dominant approach, using polymers to maintain drugs in amorphous states with higher apparent solubility. **Lipid-based formulations** gained prominence for highly lipophilic compounds. **Nanomilling** (reducing particle size to nanometer scale) became commercially viable, with drugs like rapamycin and fenofibrate using this approach.

**Clinical Impact**: Many approved drugs now rely on advanced formulation strategies the author would recognize as sophisticated "long-chain goos" and "gemisches." Examples include **Kaletra** (HIV medication using melt extrusion), **Spiriva** (tiotropium inhalation powder with elaborate particle engineering), and **Ibrance** (palbociclib with particle size reduction). However, formulation complexity contributes to high drug costs and manufacturing challenges.

**Regulatory Evolution**: The FDA established more formal guidance on pharmaceutical quality, including regulatory frameworks for complex formulations like ASDs, recognizing that "formulation is not just a delivery vehicle but integral to drug performance."

**Industry Consolidation**: Specialized formulation companies grew significantly (e.g., **Bend Research** was acquired by Capsugel, later Lonza), indicating the ongoing critical need for formulation expertise. The basic chemist-formulator dynamic described remains unchanged in most companies, though computational tools now help predict formulation needs earlier.

## 3. PREDICTIONS

The article itself doesn't make explicit forward-looking predictions but rather articulates enduring principles of formulation science. The **implicit expectations** embedded in the author's analysis and their subsequent realization include:

• **Persistence of solubility problems**: The author's tone suggests these formulation struggles were viewed as ongoing challenges rather than problems nearing solutions. This proved accurate—poor solubility remains a primary bottleneck in drug development, with modern estimates suggesting 60-90% of pipeline compounds face at least moderate solubility challenges.

• **Solution vs. suspension as bioavailability predictors**: The author's observation that "if your compound works when given as a solution but not as a suspension, then you have some serious problems" reflects what became codified as the **Biopharmaceutics Classification System (BCS)** principle that dissolution-limited absorption predicts formulation-dependent performance. This insight remains clinically validated—drugs with poor dissolution typically have variable oral bioavailability and require sophisticated formulations.

## 4. INTEREST

Rating: **7/10**

This article captured an enduring, fundamental challenge in pharmaceutical development with practical insight that remains highly relevant. While focused on an quotidian industrial process rather than groundbreaking science, the formulation bottleneck it describes continues to gatekeep drug approval and patient access, making it both prescient and practically important for understanding why promising compounds fail.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20021117-new-improved-now-stickier-lumps.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_